References
- Bensimon G, Lacomblez L, Meinenger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994; 330: 585–591.
- ALS CNTF Treatment Study (A.C.T.S.) Group. A double-blind, placebo controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyo- trophic lateral sclerosis (ALS). Neurology 1996; 46: 1244–1249.
- Cedarbaum JM, Stambler N, Brooks BR, Bradley WB. Brain-derived neurotrophic factor in amyotrophic lateral sclerosis: a failed drug or a failed trial?. Ann Neurol 1998; 44: 506–507. (Abstract).
- Groenveld GJ, Veldink JH, van der Tweel I et al. A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol 2003; 53: 437–445.
- Magnus T, Beck M, Geiss R, Puls I, Naumann M, Toyka KV. Disease progression in amyotrophic lateral sclerosis: predictors of survival. Muscle Nerve 2002; 25: 709–714.
- Lee JR-J, Annengers JF, Appel SH. Prognosis of amyotrophic lateral sclerosis and the effect of referral selection. J Neurol Sci 1995; 132: 207–215.
- Gubbay SS, Kahana E, Zilber N, Cooper G, Pintov S, Liebowitz. Amyotrophic lateral sclerosis. A study of its presentation and prognosis. Neurol 1985; 232: 295–300.
- Chancellor AM, Slattery JM, Fraser H, Swingler RJ, Holloway SM, Warlow CP. The prognosis of adult-onset motor neuron disease: a prospective study based on the Scottish Motor Neuron Disease Register. J Neurol 1993; 240: 339–346.
- Norris F, Shepherd R, Denys E et al. Onset, natural history and outcome in idiopathic adult motor neuron disease. J Neurol Sci 1993; 118: 48–55.
- Tysnes O-B, Vollset SE, Larsen JP, Aarli JA. Prognostic factors and survival in amyotrophic lateral sclerosis. Neuroepidemiology 1994; 13: 226–235.
- Haverkamp LJ, Appel V, Appel SH. Natural history of amyotrophic lateral sclerosis in a database population. Brain 1995; 118: 707–719.
- Louwerse ES, Visser CE, Bossuyt PMM, Weverling GK, Netherlands ALS Consortium. Amyotrophic lateral sclerosis: mortality risk during the course of the disease and prognostic factors. J Neurol Sci 1997; 152 (Suppl 2): S10–17.
- Armon C, Moses D. Linear estimates of rates of disease progression as predictors of survival in patients with ALS entering clinical trials. J Neurol Sci 1998; 160: S37–41.
- Thus V, Peters E, Theys P, Matthus G, Robbrecht W. Demographic characteristics and prognosis in a Flemish amyotrophic lateral sclerosis population. Acta Neurol Belg 2000; 100: 84–90.
- Turner MR, Bakker M, Sham P, Shaw CE, Leigh PN, Al-Chalabi A. Prognostic modelling of therapeutic interventions in amyo- trophic lateral sclerosis. ALS 2002; 3: 15–21.
- Sorenson EJ, Stalker AP, Kurland LT, Windebank AJ. Amyo- trophic lateral sclerosis in Olmstead County, Minnesota, 1925–1998. Neurology 2002; 59: 280–282.
- Del Aguila MA, Longstreth Jr WT, McGujire V, Koepsell TK, van Belle G. Prognosis in amyotrophic lateral sclerosis: a population- based study. Neurology 2003; 60: 813–819.